BioSpace News Archive

Hillrom announced that it will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021. John Groetelaars, Hillrom’s president and chief executive officer, will participate in a fireside chat at 9:30 a.m.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase 1 clinical trial of ALPN-202 monotherapy at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, reported financial results for the first quarter ended March 31, 2021.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced financial results for the first quarter of 2021, issued guidance for the second quarter of 2021, and raised guidance for revenue growth and reaffirmed profitability guidance for full-year 2021.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2021.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates Voyager Therapeutics on receiving FDA clearance of the IND application for their gene therapy candidate VY-HTT01 for the treatment of Huntington’s disease.

Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the first quarter of fiscal 2021 (“Q1'21"). Q1'21 total revenues were $894.8 million, up 62.4% year-over-year. Q1'21 Clear Aligner revenues were $753.3 million, up 56.4% year-over-year and Q1'21 Imaging Systems and CAD/CAM Services revenues were $141.5 million, up 104.0% year-over-year. Q1'21 Clear Aligner volume was 595.8 thousand cases, up 65.8% year-over-year.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that it will release first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021.